Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 1;35(1):49-53.
doi: 10.4274/tjh.2017.0095. Epub 2017 Nov 13.

NPM1 Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction

Affiliations

NPM1 Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction

Dushyant Kumar et al. Turk J Haematol. .

Abstract

Objective: Nucleophosmin-1 (NPM1) mutations have prognostic importance in acute myeloid leukemia (AML) patients with intermediate-risk karyotype at diagnosis. Approximately 30% of newly diagnosed cytogenetically normal AML (CN-AML) patients harbor the NPM1 mutation in India. In this study we compared the efficiency of three molecular techniques in detecting NPM1 mutation in peripheral blood and bone marrow samples.

Materials and methods: In a single-center cohort we analyzed 165 CN-AML bone marrow/peripheral blood samples for NPM1 mutation analysis. About 30% of the CN-AML samples revealed NPM1 mutations. For the detection, three methods were compared: Sanger sequencing, pyrosequencing, and real-time polymerase chain reaction (PCR).

Results: NPM1 exon 12 mutations were observed in 52 (31.51%) of all CN-AML cases. The sensitivity of Sanger sequencing, pyrosequencing, and real-time PCR was 80%, 90%, and 95%, whereas specificity was 95%, 100%, and 100%, respectively. The minimum limit of mutation detection was 20%-30% for Sanger sequencing, 1%-5% for pyrosequencing, and 0.1%-1% for real-time PCR.

Conclusion: The sequencing method, which is the reference method, has the lowest sensitivity and is sometimes difficult to interpret. Real-time PCR is a highly sensitive method for mutation detection but is limited for specific mutation types. In our study, pyrosequencing emerged as the most suitable technique for the detection of NPM1 mutations on the basis of its easy interpretation and less time-consuming processes than Sanger sequencing.

Amaç: Nükleofosmin-1 (NPM1) mutasyonları tanı anında orta risk akut miyeloid lösemi (AML) hastalarında prognostik öneme sahiptir. Hindistan’da, yeni teşhis normal sitogenetiğe sahip AML (CN-AML) hastalarının yaklaşık %30’u NPM1 pozitiftir. Bu çalışmada periferik kan ve kemik iliği örneklerinde NPM1 mutasyonu saptamada kullanılan üç moleküler tekniğin etkinliğini karşılaştırdık. Gereç ve Yöntemler: Tek merkezli bu kohortta, 165 CN-AML kemik iliği/periferik kan örneklerinde NPM1 mutasyon analizi yapıldı. CN-AML örneklerinin yaklaşık %30’unda NPM1 mutasyonu saptandı. Mutasyonun taranmasında üç yöntem karşılaştırıldı: Sanger dizileme, pirodizileme, gerçek-zamanlı polimeraz zincir reaksiyonu (PCR). Bulgular: Tüm CN-AML olgularının 52’sinde (%31,51) NPM1 exon12 mutasyonları gözlendi. Sanger dizileme, pirodizileme ve gerçek zamanlı PCR’nin duyarlılıkları sırasıyla %80, %90 ve %95 iken, özgünlükleri %95, %100 ve %100’dü. Mutasyonun saptanmasında minimum limit Sanger dizileme yöntemi için %20-%30, pirodizilemede %1-5, ve gerçek-zamanlı PCR için %0,1-%1 idi. Sonuç: Referans yöntemi olan dizileme yöntemi, en düşük duyarlılığa sahiptir ve bazen yorumlaması güçtür. Gerçek-zamanlı PCR mutasyon saptamada yüksek duyarlılığa sahip bir yöntemdir fakat özel mutasyon tipleri için sınırlıdır. Çalışmamızda, pirodizileme yönteminin kolay yorumlanması ve Sanger dizileme yönteminden daha az zaman harcanan işlem olması esasına dayanarak NPM1 mutasyonun saptanmasında en uygun teknik olduğu sonucuna varılmıştır.

Keywords: Acute myeloid leukemia Mutation analysis.; NPM1; Pyrosequencing.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

Figures

Figure 1
Figure 1. NPM1 mutation detection by pyrosequencing detection by pyrosequencing.
Figure 2
Figure 2. A) NPM1 mutation detection by real-time polymerase chain reaction using Ipsogen MutaScreen Kit. B) Sanger sequencing.

Similar articles

Cited by

References

    1. Naoe T, Suzuki T, Kiyoi H, Urano T. Nucleophosmin: a versatile molecule associated with hematological malignancies. Cancer Sci. 2006;97:963–969. - PMC - PubMed
    1. Zhao T, Zhu HH, Wang J, Jia JS, Yang SM, Jiang H, Lu J, Chen H, Xu LP, Zhang XH, Jiang B, Ruan GR, Wang DB, Huang XJ, Jiang Q. Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients. Zhonghua Xue Ye Xue Za Zhi. 2013;38:10–16. - PMC - PubMed
    1. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B, Valk PJ. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747–3754. - PubMed
    1. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254–266. - PubMed
    1. Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U. Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia. 2007;21:366–367. - PubMed

LinkOut - more resources